KBC Group NV Sells 2,112 Shares of Solventum Co. (NYSE:SOLV)

KBC Group NV decreased its holdings in Solventum Co. (NYSE:SOLV) by 6.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 28,467 shares of the company’s stock after selling 2,112 shares during the quarter. KBC Group NV’s holdings in Solventum were worth $1,985,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of SOLV. Davis Selected Advisers bought a new stake in shares of Solventum during the second quarter worth $273,070,000. Nuance Investments LLC bought a new stake in shares of Solventum during the second quarter worth $115,829,000. Newport Trust Company LLC bought a new stake in shares of Solventum during the second quarter worth $98,976,000. Baupost Group LLC MA bought a new stake in shares of Solventum during the second quarter worth $96,242,000. Finally, Magnetar Financial LLC grew its stake in shares of Solventum by 2,880.8% during the second quarter. Magnetar Financial LLC now owns 1,490,410 shares of the company’s stock worth $78,813,000 after purchasing an additional 1,440,410 shares during the period.

Solventum Stock Down 0.5 %

NYSE:SOLV opened at $67.12 on Tuesday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock has a 50-day moving average price of $70.54 and a two-hundred day moving average price of $62.20.

Analyst Ratings Changes

A number of equities research analysts recently commented on SOLV shares. Piper Sandler lifted their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Stifel Nicolaus started coverage on Solventum in a research note on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective for the company. Morgan Stanley lifted their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. The Goldman Sachs Group lifted their price objective on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. Finally, Wells Fargo & Company decreased their price objective on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Solventum has an average rating of “Hold” and an average price target of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.